Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat ...

Bausch + Lomb (BLCO) announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, ...

the developer of a novel minimally invasive glaucoma surgery (MIGS) procedure. According to InvestingPro data, BLCO has demonstrated strong momentum with a 38% price return over the past six ...

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report), retaining the price target of ...